BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.
BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS:Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.
Authors: P Erickson; J Gao; K S Chang; T Look; E Whisenant; S Raimondi; R Lasher; J Trujillo; J Rowley; H Drabkin Journal: Blood Date: 1992-10-01 Impact factor: 22.113
Authors: Mette K Andersen; Richard A Larson; Nils Mauritzson; Susanne Schnittger; Suresh C Jhanwar; Jens Pedersen-Bjergaard Journal: Genes Chromosomes Cancer Date: 2002-04 Impact factor: 5.006
Authors: Steven Lane; Russell Saal; Peter Mollee; Mark Jones; Andrew Grigg; Kerry Taylor; John Seymour; Glen Kennedy; Bronwyn Williams; Karen Grimmett; Vanessa Griffiths; Devinder Gill; Matthew Hourigan; Paula Marlton Journal: Leuk Lymphoma Date: 2008-03
Authors: Alan K Burnett; Keith Wheatley; Anthony H Goldstone; Richard F Stevens; Ian M Hann; John H K Rees; Georgina Harrison Journal: Br J Haematol Date: 2002-08 Impact factor: 6.998
Authors: P Liu; S A Tarlé; A Hajra; D F Claxton; P Marlton; M Freedman; M J Siciliano; F S Collins Journal: Science Date: 1993-08-20 Impact factor: 47.728
Authors: R F Schlenk; A Benner; J Krauter; T Büchner; C Sauerland; G Ehninger; M Schaich; B Mohr; D Niederwieser; R Krahl; R Pasold; K Döhner; A Ganser; H Döhner; G Heil Journal: J Clin Oncol Date: 2004-08-02 Impact factor: 44.544
Authors: John C Byrd; Amy S Ruppert; Krzysztof Mrózek; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Judith Stamberg; Prasad R K Koduru; Joseph O Moore; Robert J Mayer; Frederick R Davey; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 44.544
Authors: Jürgen Krauter; Kerstin Gorlich; Oliver Ottmann; Michael Lubbert; Hartmut Dohner; Wolfgang Heit; Lothar Kanz; Arnold Ganser; Gerhard Heil Journal: J Clin Oncol Date: 2003-12-01 Impact factor: 44.544
Authors: F V Michelis; E G Atenafu; V Gupta; D D Kim; J Kuruvilla; J H Lipton; D Loach; M D Seftel; J Uhm; N Alam; A Lambie; L McGillis; H A Messner Journal: Bone Marrow Transplant Date: 2015-03-30 Impact factor: 5.483
Authors: Mohammad Faizan Zahid; Aric Parnes; Bipin N Savani; Mark R Litzow; Shahrukh K Hashmi Journal: World J Stem Cells Date: 2016-08-26 Impact factor: 5.326
Authors: Paul B Koller; Hagop M Kantarjian; Graciela M Nogueras-Gonzalez; Elias Jabbour; Srdan Verstovsek; Gautam Borthakur; Zeev Estrov; William G Wierda; Guillermo Garcia-Manero; Alessandra Ferrajoli; Farhad Ravandi; Susan M O'Brien; Jorge E Cortes Journal: Cancer Date: 2016-10-20 Impact factor: 6.860